Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. - Wikidata - awgldk - TriplyDB

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis.

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis.

http://www.wikidata.org/entity/Q36534239

about

Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis.Estimating progression rates for human papillomavirus infection from epidemiological data.A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan.Cost-effectiveness of different human papillomavirus vaccines in Singapore Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study Impact of genital warts on health related quality of life in men and women in mainland China: a multicenter hospital-based cross-sectional study.Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.Inference of type-specific HPV transmissibility, progression and clearance rates: a mathematical modelling approach Patient experience - the ingredient missing from cost-effectiveness calculations.[Efficacy of commercially available vaccines against HPV infection in women: a systematic review and meta-analysis].Applying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran.Systematic review of the cost-effectiveness of the vaccination against HPV in Brazil.Economic evaluation of human papillomavirus vaccination in the United Kingdom.Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial.Modeling preventative strategies against human papillomavirus-related disease in developed countries Perianal condylomas, anal squamous intraepithelial neoplasms and screening: a review of the literature.Economic evaluation of human papilloma virus vaccination in the European Union: a critical review.Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.Economic and humanistic burden of external genital warts.Impact of model calibration on cost-effectiveness analysis of cervical cancer prevention.Applying reinforcement learning techniques to detect hepatocellular carcinoma under limited screening capacity.Projected cervical Cancer incidence in Swaziland using three methods and local survey estimates.

P2860

Q30878077-32C1E96F-241A-465D-B4E6-F288C3A1118C Q33467330-5BAF2CEE-09F3-44D2-819A-ADD058EC1C45 Q33514126-90E1FA1E-632E-40F4-91E5-74A3BFDEDA3C Q33523171-BAA336B5-E8E9-48F0-B27F-89BD755560FC Q33859018-BC043C6D-14FB-4412-81DF-278EC3CCEBB1 Q33930993-981B6610-B4DD-4167-9C9A-80260C65AD32 Q34180616-D7C92B33-E716-4688-B906-5749ADB71377 Q34461262-598054A4-5233-4F41-B8EB-287852E79E0E Q34490267-A2B7E28F-C3AE-405A-B7AD-87D86E2FB53F Q35117858-5C4AA6FB-194A-4B57-9E3F-5CB8DFD6D8D7 Q35427518-A44B0E6E-C07C-43ED-9D2B-8B449B6B10DE Q35484171-DBC6ED8E-70D7-41EE-B543-74137CEAFE14 Q35886544-476CA322-0972-4775-A4D9-29739630CFEB Q36818045-6B64E859-74D7-47DC-A6A7-87B624EF8E11 Q36843345-FFB1D96C-AE19-4497-AC6B-298D86908BCC Q37198208-F3B11B2A-3771-407B-BCEB-210F20D94CF1 Q37722093-C6FE4C5B-D6C5-45D8-AE64-1E5C43F8CD49 Q37839828-550964A4-53C3-481D-B62F-F13D1A973A4C Q37916532-C7CC05C9-D6BB-414B-A3B1-5126AAA9E8CD Q37937705-59D4B391-3A6C-40BD-9E5E-43E800FF5743 Q37971472-D0D29DD8-10EE-4968-8C56-7980477CB262 Q47100259-1CC916CF-AB65-458D-AA94-1CBF0BD0CE78 Q50629271-A6C0F320-2579-4625-A894-D0396437E1F4 Q55438912-450AB073-2448-4538-AFDF-7F3CBAAC7A30

P2860

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis.

http://www.wikidata.org/entity/Q36534239

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Adding a quadrivalent human pa ...... A cost-effectiveness analysis.

@ast

Adding a quadrivalent human pa ...... A cost-effectiveness analysis.

@en

type

label

Adding a quadrivalent human pa ...... A cost-effectiveness analysis.

@ast

Adding a quadrivalent human pa ...... A cost-effectiveness analysis.

@en

prefLabel

Adding a quadrivalent human pa ...... A cost-effectiveness analysis.

@ast

Adding a quadrivalent human pa ...... A cost-effectiveness analysis.

@en

P1433

Q36534239-7C5892A4-36FD-4A95-84DE-F0B3FBD04880

P1476

Q36534239-8D84F432-28DF-4716-825F-BD76FCE0BEF2

P2093

Q36534239-1E315C02-4C05-459C-93B5-BC7B52A13BC3

Q36534239-9ED378FB-0E65-489B-BD6D-3AE879E62534

Q36534239-ADEDFDD1-41BB-41B6-957A-E552669B0A15

Q36534239-CD9AABC7-34B5-42A0-B02F-8501A63F4A52

Q36534239-EAD30A2A-28FA-48C9-8BA9-BD07EE2B1573

P2860

Q36534239-0147BAF7-A96C-4F41-A822-4326D4133AC1

Q36534239-034D7986-CDE6-49FA-AAAF-5C42DE26DDCD

Q36534239-0F7A8609-7B91-47B3-A3E1-46A0CB259BB7

Q36534239-179FA84F-619D-4408-B939-BCC92321BB18

Q36534239-1A586918-B251-46E9-93AA-1E7AFFACBE4D

Q36534239-1DC13AFD-4C4C-4E05-8CC6-959F4A0A02F7

Q36534239-28CE2CEF-48B8-4575-8066-6651A43C59B8

Q36534239-29A4EC95-2B9D-4D8C-8D11-830399DAD4E1

Q36534239-2FA1FC26-414E-4221-8BEF-51D21CC91C96

Q36534239-3AC65D5F-DAD2-4FBD-B6B8-639F9F6F4B6D

P2888

Q36534239-6A3C68D2-F235-41ED-B575-7122DC6534D9

P304

Q36534239-AE147EA3-5883-4849-8570-8294106D6821

P31

Q36534239-4E3037B1-55A5-42C2-ABBA-491F47F25B25

P356

Q36534239-18A01F1F-C619-40D5-B225-CCC340B1D4C5

P478

Q36534239-10295E1B-C76C-4D25-8C67-2A4A3FDB23F0

P577

Q36534239-28202CC8-CDDA-45DA-BAD4-5CD90C0A077E

P5875

Q36534239-083F0596-DE25-4CBB-AA13-E8A753967C87

P6179

Q36534239-39484211-00E7-4C21-93A3-54D2CDFACCF6

P698

Q36534239-27D13A41-51AD-46D5-8A36-BCF8787C10AF

P932

Q36534239-1EC63395-4953-4687-B06E-3A7B561320BF

P356

P1433

Cost Effectiveness and Resource Allocation

P1476

Adding a quadrivalent human pa ...... A cost-effectiveness analysis.

@en

P2093

Evan R Myers

http://www.w3.org/2001/XMLSchema#string

Nathalie Largeron

http://www.w3.org/2001/XMLSchema#string

Ruanne V Barnabas

http://www.w3.org/2001/XMLSchema#string

Shalini L Kulasingam

http://www.w3.org/2001/XMLSchema#string

Steve Benard

http://www.w3.org/2001/XMLSchema#string

P2860

Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

Genital warts: current and future management options.

Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.

Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis.

Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia.

P2888

P304

4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1478-7547-6-4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5571672

http://www.w3.org/2001/XMLSchema#string

P6179

1018952625

http://www.w3.org/2001/XMLSchema#string

P698

18279515

http://www.w3.org/2001/XMLSchema#string

P932

2290741

http://www.w3.org/2001/XMLSchema#string